Trust Point’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$380K Buy
702
+40
+6% +$20.7K 0.03% 319
2026
Q2
$359K Sell
662
-19
-3% -$10.7K 0.03% 296
2026
Q1
$404K Sell
681
-27
-4% -$13.4K 0.04% 303
2025
Q4
$345K Sell
708
-518
-42% -$241K 0.03% 333
2025
Q3
$514K Buy
1,226
+283
+30% +$95.2K 0.04% 224
2025
Q2
$271K Sell
943
-274
-23% -$81.9K 0.03% 317
2025
Q1
$375K Sell
1,217
-480
-28% -$164K 0.03% 285
2024
Q4
$599K Buy
1,697
+531
+46% +$195K 0.04% 256
2024
Q3
$418K Buy
1,166
+257
+28% +$86.8K 0.03% 316
2024
Q2
$290K Buy
+909
New +$241K 0.02% 384

Other funds holding UTHR

Trust Point's UTHR Position: Q3 2026 in Review

Trust Point increased its United Therapeutics (UTHR) stake by 6% in Q3 2026, buying an estimated $20.7K and bringing the position to 702 shares worth $380K. The position accounts for 0.03% of the portfolio, ranked #319.

Trust Point first reported a position in UTHR in Q2 2024 and has held it in 10 quarters since. The position peaked at $599K in Q4 2024. 673 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Trust Point held 702 shares of United Therapeutics worth $380K as of Q3 2026.
  • Trust Point bought 40 United Therapeutics shares in Q3 2026, an estimated $20.7K.
  • United Therapeutics made up 0.03% of Trust Point's portfolio in Q3 2026, its #319 holding.
  • Trust Point first reported a position in United Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • Trust Point's United Therapeutics position peaked at $599K in Q4 2024.
  • 673 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.